A comparison of droperidol and metoclopramide in the treatment of nausea and vomiting during cis-platinum polichemotherapy in ovarian carcinoma.
A comparison was made of the anti-emetic effects of Droperidol (total dose: 5 mg e.v.) and Metoclopramide (total dose: 30 mg e.v.), on 7 patients affected by advanced ovarian carcinoma and undergoing polychemotherapeutical treatment with courses including 50 mg/mq-doses of Cis-Dichlorodiaminoplatinum (DDP). Although no significant difference was observed between the emetic-control effects of the two substances, Droperidol was preferred by all patients, owing to its subjective effects.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects*; D004329:Droperidol / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000970:Antineoplastic Agents; D008787:Metoclopramide; D004329:Droperidol; D002945:Cisplatin